PLYMOUTH, Minn., Aug. 4 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV),
a global endovascular device company, today announced the appointment of
Douglas W. Kohrs to its Board of Directors effective immediately. Mr. Kohrs
will also serve as a member of the Compensation Committee. Mr. Kohrs
previously served as a director of ev3 from June 2005 until October 2007 at
which time Mr. Kohrs voluntarily resigned in order to facilitate the
completion of ev3's acquisition of FoxHollow Technologies, Inc.
Mr. Kohrs is the President and Chief Executive Officer of Tornier B.V., a
privately held global orthopedic company. Prior to joining Tornier B.V., Mr.
Kohrs served as Chief Executive Officer of American Medical Systems Holdings,
Inc. from April 1999 until January 2005. He served on the board of directors
of American Medical Systems Holdings from 1999 to May 2006, and served as
chairman of the board from March 2004 to May 2006. Mr. Kohrs is a member of
the board of directors Tornier B.V. and The Institute for Health Technology
Studies (InHealth), a not-for-profit medical device research organization.
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to developing
innovative, breakthrough and clinically proven technologies and solutions for
the treatment of lower extremity vascular and neurovascular diseases. ev3's
products are used by endovascular specialists to treat a wide range of
peripheral vascular and neurovascular diseases and disorders. The company
offers a comprehensive portfolio of treatment options, including the primary
interventional technologies used today -- peripheral angioplasty balloons,
stents, plaque excision systems, embolic protection devices, liquid embolics,
embolization coils, thrombectomy catheters and occlusion balloons. More
information about the company and its products can be found at
http://www.ev3.net.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.
and other countries.
SOURCE ev3 Inc.
